TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 0.900nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 1.70nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 2.30nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 2.30nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 3.20nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 3.5nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 4nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 4.10nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 4.20nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 4.30nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 4.60nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 4.70nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 5.20nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 5.80nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 6nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 6.80nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 7.90nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 7.90nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 8.30nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 8.5nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 10.4nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 17.8nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 19.1nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 23.4nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 46.5nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 61.3nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 67.5nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 69.6nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 70.3nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 72nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 87.2nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 197nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 232nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 414nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataKi: 1.40E+3nMAssay Description:The CCR3 receptor binding assay was performed in a Scintillation Proximity Assay (SPA) design with the radioligand recombinant human 125Iodine-eotaxi...More data for this Ligand-Target Pair
Affinity DataIC50: 0.200nMAssay Description:In vitro kinase enzyme assay using Jak3, Jak2, Jak1, and Tyk2.More data for this Ligand-Target Pair
Affinity DataIC50: 0.300nMAssay Description:In vitro kinase enzyme assay using Jak3, Jak2, Jak1, and Tyk2.More data for this Ligand-Target Pair
Affinity DataIC50: 0.600nMAssay Description:In vitro kinase enzyme assay using Jak3, Jak2, Jak1, and Tyk2.More data for this Ligand-Target Pair
Affinity DataIC50: 0.650nMAssay Description:Compounds were seeded into assay-ready plates (Greiner 384 low volume, cat. no. 784900) using an Echo 555 acoustic dispenser, and dimethyl sulfoxide ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:IC50 values were determined using 12 point 2-fold dilutions (starting from 10 μM).More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair